¿Qué hemos aprendido en estos dos años del manejo del paciente con Cáncer de Pulmón No Microcítico en segunda línea de tratamiento con Inmunoterapia?

9 / 27

Brahmer J. et al. AACR 2017 1301PD
Best Change in Target Lesion Tumor Burden
to First Progression in 5-Year Survivorsa
CA209-003 5-Year Update: Phase 1 Nivolumab in Advanced NSCLC
62
0
-27 -28
-42 -48
-57 -57 -62 -66 -67 -71 -71
-83
-93 -93
-120
-90
-60
-30
0
30
60
90
Change in tumor size (%)
aTumor assessments were performed at the end of every nivolumab treatment cycle and during the follow-up period; except for patients who
discontinued due to worsening PD, all patients were followed from the last visit until relapse, initiation of a new therapy, or a total of 1 year
follow-up, whichever occurred first
Dashed horizontal line denotes 30% decrease for partial response (in the absence of new lesions)